Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML.
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Cytarabine
/ therapeutic use
Daunorubicin
/ therapeutic use
Docosahexaenoic Acids
/ therapeutic use
Eicosapentaenoic Acid
Emulsions
/ therapeutic use
Feasibility Studies
Fish Oils
/ therapeutic use
Humans
Induction Chemotherapy
Leukemia, Myeloid, Acute
/ genetics
NF-E2-Related Factor 2
/ genetics
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
13 06 2022
13 06 2022
Historique:
received:
28
09
2021
accepted:
26
05
2022
entrez:
13
6
2022
pubmed:
14
6
2022
medline:
16
6
2022
Statut:
epublish
Résumé
The treatment of acute myeloid leukemia (AML) with unfavorable cytogenetics treatment remains a challenge. We previously established that ex vivo exposure of AML blasts to eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), or fish oil emulsion (FO) induces Nrf2 pathway activation, metabolic switch, and cell death. The FILO group launched a pilot clinical study to evaluate the feasibility, safety, and efficacy of the adjunction of a commercial FO emulsion to 3 + 7 in untreated AML with unfavorable cytogenetics. The primary objective was complete response (CR). Thirty patients were included. FO administration raised the plasma levels of eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids (p < 0.001). The pharmacokinetics of cytarabine and daunorubicin were unaffected. A historical comparison to the LAM2001 trial (Lioure et al. Blood 2012) found a higher frequency of grade 3 serious adverse events, with no drug-related unexpected toxicity. The CR rate was 77%, and the partial response (PR) 10%, not significantly superior to that of the previous study (CR 72%, PR 1%). RT-qPCR analysis of Nrf2 target genes and antioxidant enzymes did not show a significant in vivo response. Overall, FO emulsion adjunction to 3 + 7 is feasible. An improvement in CR was not shown in this cohort of high-risk patients. The present data does not support the use of FO in adjunction with 3 + 7 in high-risk AML patients.ClinicalTrials.gov identifier: NCT01999413.
Identifiants
pubmed: 35697729
doi: 10.1038/s41598-022-13626-y
pii: 10.1038/s41598-022-13626-y
pmc: PMC9192636
doi:
Substances chimiques
Emulsions
0
Fish Oils
0
NF-E2-Related Factor 2
0
Cytarabine
04079A1RDZ
Docosahexaenoic Acids
25167-62-8
Eicosapentaenoic Acid
AAN7QOV9EA
Daunorubicin
ZS7284E0ZP
Banques de données
ClinicalTrials.gov
['NCT01999413']
Types de publication
Clinical Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
9748Informations de copyright
© 2022. The Author(s).
Références
PLoS One. 2012;7(4):e35102
pubmed: 22496896
Sci Rep. 2017 Jul 6;7(1):4826
pubmed: 28684736
Br J Cancer. 1994 Aug;70(2):324-9
pubmed: 7914424
Cancer Chemother Pharmacol. 2008 Apr;61(5):847-53
pubmed: 17609947
Biometrics. 1982 Mar;38(1):143-51
pubmed: 7082756
Blood. 2019 Jan 3;133(1):7-17
pubmed: 30361262
Cancer Chemother Pharmacol. 2012 May;69(5):1155-63
pubmed: 22212298
Cancer Biol Ther. 2009 Feb;8(4):331-7
pubmed: 19197149
Clin Nutr. 2014 Apr;33(2):226-39
pubmed: 24084088
J Hum Nutr Diet. 2017 Dec;30(6):681-692
pubmed: 28374923
Cancer Treat Rev. 2013 Aug;39(5):473-88
pubmed: 22850619
Genome Biol. 2002 Jun 18;3(7):RESEARCH0034
pubmed: 12184808
Pharmacol Res. 2018 Oct;136:45-55
pubmed: 30142422
Nutrition. 2016 Jan;32(1):41-7
pubmed: 26421385
Intensive Care Med. 2003 Sep;29(9):1472-81
pubmed: 12897994
Br J Cancer. 2009 Dec 15;101(12):1978-85
pubmed: 19920822
Am J Respir Crit Care Med. 2003 May 15;167(10):1321-8
pubmed: 12615625
J Clin Oncol. 2018 Sep 10;36(26):2684-2692
pubmed: 30024784
Cancer Chemother Pharmacol. 2016 Nov;78(5):1051-1058
pubmed: 27738808
Mol Pharmacol. 2007 Dec;72(6):1545-56
pubmed: 17878267
Nutr J. 2015 Jan 21;14:9
pubmed: 25609264
Haematol Blood Transfus. 1987;30:283-7
pubmed: 3476358
Biochem Pharmacol. 2001 Oct 1;62(7):821-8
pubmed: 11543718
Cancer Chemother Pharmacol. 1995;36(5):425-30
pubmed: 7634384
Int J Mol Sci. 2016 Aug 03;17(8):
pubmed: 27527148
Blood. 2017 Aug 10;130(6):722-731
pubmed: 28588020
Blood. 2012 Mar 22;119(12):2943-8
pubmed: 22323482
Leukemia. 2019 Feb;33(2):379-389
pubmed: 30555165
Crit Care. 2010;14(1):R5
pubmed: 20085628
N Engl J Med. 2018 Jun 21;378(25):2386-2398
pubmed: 29860938
Cancer Res. 2014 Jun 1;74(11):3092-103
pubmed: 24699624
Lipids Health Dis. 2017 Jun 2;16(1):104
pubmed: 28578704
J Biol Chem. 2011 Aug 5;286(31):27092-102
pubmed: 21659508
N Engl J Med. 2017 Aug 3;377(5):454-464
pubmed: 28644114
Cancer Chemother Pharmacol. 1979;2(1):15-7
pubmed: 498413